These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1501734)

  • 1. Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations.
    Kampf D; Eckardt KU; Fischer HC; Schmalisch C; Ehmer B; Schostak M
    Nephron; 1992; 61(4):393-8. PubMed ID: 1501734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of recombinant human erythropoietin in chronic haemodialysis patients.
    Nielsen OJ
    Pharmacol Toxicol; 1990 Feb; 66(2):83-6. PubMed ID: 2315268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth hormone responses to growth hormone-releasing hormone and clonidine before and after erythropoietin therapy in CAPD patients.
    Díez J; Iglesias P; Sastre J; Méndez J; Selgas R; Gómez-Pan A
    Nephron; 1996; 74(3):548-54. PubMed ID: 8938679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or continuous ambulatory peritoneal dialysis.
    Stockenhuber F; Loibl U; Gottsauner-Wolf M; Jahn C; Manker W; Meisl TF; Balcke P
    Nephron; 1991; 59(3):399-402. PubMed ID: 1758528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous, and intraperitoneal routes in continuous ambulatory peritoneal dialysis (CAPD) patients.
    Boelaert JR; Schurgers ML; Matthys EG; Belpaire FM; Daneels RF; De Cre MJ; Bogaert MG
    Perit Dial Int; 1989; 9(2):95-8. PubMed ID: 2488207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous erythropoietin in the treatment of renal anaemia.
    Drinovec J; Varl J
    Przegl Lek; 1992; 49(1-2):38-40. PubMed ID: 1455004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
    Lui SF; Chung WW; Leung CB; Chan K; Lai KN
    Clin Nephrol; 1990 Jan; 33(1):47-51. PubMed ID: 2302870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daily subcutaneous administration of recombinant human erythropoietin (rhEPO) in peritoneal dialysis patients: a European dose-response study.
    Faller B; Slingeneyer A; Waller M; Michel C; Grützmacher P; Müller HP; Barany P; Grabensee B; Issad B; Schmitt H
    Clin Nephrol; 1993 Sep; 40(3):168-75. PubMed ID: 8403573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of low-dose subcutaneous recombinant human erythropoietin in end-stage renal disease: experience with children receiving continuous cycling peritoneal dialysis.
    Ongkingco JR; Ruley EJ; Turner ME
    Am J Kidney Dis; 1991 Oct; 18(4):446-50. PubMed ID: 1928063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
    Macdougall IC; Roberts DE; Neubert P; Dharmasena AD; Coles GA; Williams JD
    Lancet; 1989 Feb; 1(8635):425-7. PubMed ID: 2563798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of recombinant human erythropoietin in children treated with continuous ambulatory peritoneal dialysis.
    Reddingius RE; Schröder CH; Koster AM; Monnens LA
    Eur J Pediatr; 1994 Nov; 153(11):850-4. PubMed ID: 7843202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and hematologic response to subcutaneous administration of recombinant human erythropoietin in children undergoing long-term peritoneal dialysis: a multicenter study.
    Montini G; Zacchello G; Perfumo F; Edefonti A; Bassi S; Cantaluppi A; Sarchi C; Cazzin M; Ferrari V; Boccazzi A
    J Pediatr; 1993 Feb; 122(2):297-302. PubMed ID: 8429450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease.
    Muirhead N; Churchill DN; Goldstein M; Nadler SP; Posen G; Wong C; Slaughter D; Laplante P
    Am J Nephrol; 1992; 12(5):303-10. PubMed ID: 1488998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of epoetin in haemodialysis patients after subcutaneous administration: influence of chronic treatment.
    Schouten JP; Voorhorst G; Helbing AR; Janssen JW; Diderich PP; Op de Hoek CT
    Pharm World Sci; 1993 Dec; 15(6):252-6. PubMed ID: 8298584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in intravenous and subcutaneous application of recombinant human erythropoietin: a multicenter trial.
    Schaller R; Sperschneider H; Thieler H; Dutz W; Hans S; Voigt D; Marx M; Engelmann J; Schöter KH; Scigalla P
    Artif Organs; 1994 Aug; 18(8):552-8. PubMed ID: 7993190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma.
    Osterborg A; Boogaerts MA; Cimino R; Essers U; Holowiecki J; Juliusson G; Jäger G; Najman A; Peest D
    Blood; 1996 Apr; 87(7):2675-82. PubMed ID: 8639883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Low doses of recombinant erythropoietin in the treatment of renal anemia in patients on chronic hemodialysis and ambulatory peritoneal dialysis].
    Lashutin SV; Nikolaev AIu; Ermolenko VM; Shutov EV; Bezruk VG; Ivashchenko MA
    Ter Arkh; 1999; 71(6):61-3. PubMed ID: 10420460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease.
    Macdougall IC; Robson R; Opatrna S; Liogier X; Pannier A; Jordan P; Dougherty FC; Reigner B
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1211-5. PubMed ID: 17699350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes.
    Ghio R; Balleari E; Ballestrero A; Gatti AM; Mareni C; Massa G; Patrone F; Sessarego M; Timitilli S
    Acta Haematol; 1993; 90(2):58-64. PubMed ID: 8285019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of intramuscular versus subcutaneous erythropoietin for the treatment of anemia in CAPD patients.
    Abreo K; Lubom JA; Collier L; Fleming D; Work J
    Adv Perit Dial; 1994; 10():124-8. PubMed ID: 7999809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.